Literature DB >> 21523521

Elevated serum γ-glutamyltransferase predicts the development of impaired glucose metabolism in middle-aged and elderly Chinese.

Yu Xu1, Min Xu, Yun Huang, Tiange Wang, Mian Li, Yaohua Wu, Aiyun Song, Xiaoying Li, Yufang Bi, Guang Ning.   

Abstract

The aim of this article is to prospectively investigate the association of the liver enzyme γ-glutamyltransferase (GGT) with the development of diabetes and impaired glucose regulation (IGR) in a Chinese population. Seven hundred and sixty normoglycaemic subjects aged 40 years or older randomly selected from an urban community of Shanghai received a baseline investigation in May 2005. The participants were invited to receive a standard 75-g oral glucose tolerance test (OGTT) in November 2008. Incident diabetes and IGR were determined according to the 1999 WHO criteria. Serum GGT levels were significantly associated with incident diabetes or combined diabetes and IGR prospectively. After extensive adjustment, the diabetes risk was significantly increased with incrementing serum GGT quartiles (P value for trend = 0.0027). As compared with the lowest quartile of GGT, the highest quartile had an adjusted hazard ratio of 1.30 (95% CI 1.03-1.65) for developing combined diabetes and IGR. Furthermore, a high serum GGT level at baseline was independently associated with an increase in the index of homeostasis model assessment of insulin resistance (HOMA-IR) at follow-up. Serum GGT concentration, even within its normal range, is a risk marker for developing impaired glucose metabolism in middle-aged and elderly Chinese.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523521     DOI: 10.1007/s12020-011-9468-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  24 in total

1.  Induction of hepatic microsomal gamma-glutamyltransferase activity following chronic alcohol consumption.

Authors:  R Teschke; A Brand; G Strohmeyer
Journal:  Biochem Biophys Res Commun       Date:  1977-04-11       Impact factor: 3.575

Review 2.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

3.  Images in cardiovascular medicine. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity.

Authors:  Aldo Paolicchi; Michele Emdin; Erri Ghliozeni; Eugenio Ciancia; Claudio Passino; George Popoff; Alfonso Pompella
Journal:  Circulation       Date:  2004-03-23       Impact factor: 29.690

4.  Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults.

Authors:  Elfriede Ruttmann; Larry J Brant; Hans Concin; Günter Diem; Kilian Rapp; Hanno Ulmer
Journal:  Circulation       Date:  2005-09-26       Impact factor: 29.690

5.  Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction.

Authors:  M Emdin; C Passino; C Michelassi; F Titta; A L'abbate; L Donato; A Pompella; A Paolicchi
Journal:  Eur Heart J       Date:  2001-10       Impact factor: 29.983

6.  Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study.

Authors:  Douglas S Lee; Jane C Evans; Sander J Robins; Peter W Wilson; Irene Albano; Caroline S Fox; Thomas J Wang; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-09       Impact factor: 8.311

7.  Serum gamma-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors.

Authors:  D-J Kim; J-H Noh; N-H Cho; B-W Lee; Y-H Choi; J-H Jung; Y-K Min; M-S Lee; M-K Lee; K-W Kim
Journal:  Diabet Med       Date:  2005-09       Impact factor: 4.359

8.  Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.

Authors:  Earl S Ford; Matthias B Schulze; Manuela M Bergmann; Claus Thamer; Hans-Georg Joost; Heiner Boeing
Journal:  Diabetes Care       Date:  2008-03-17       Impact factor: 19.112

9.  Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study.

Authors:  Yasufumi Doi; Michiaki Kubo; Koji Yonemoto; Toshiharu Ninomiya; Masanori Iwase; Yumihiro Tanizaki; Kentaro Shikata; Mitsuo Iida; Yutaka Kiyohara
Journal:  Obesity (Silver Spring)       Date:  2007-07       Impact factor: 5.002

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  4 in total

1.  New evidence for an association between liver enzymes and pancreatic islet β-cell dysfunction in young obese patients.

Authors:  Li Wang; Juanjuan Zhang; Bokai Wang; Yuwen Zhang; Jie Hong; Yifei Zhang; Weiqing Wang; Weiqiong Gu
Journal:  Endocrine       Date:  2013-04-03       Impact factor: 3.633

2.  Hemoglobin concentration and incident metabolic syndrome: a population-based large-scale cohort study.

Authors:  Yoshitaka Hashimoto; Muhei Tanaka; Toshihiro Kimura; Noriyuki Kitagawa; Masahide Hamaguchi; Mai Asano; Masahiro Yamazaki; Yohei Oda; Hitoshi Toda; Naoto Nakamura; Michiaki Fukui
Journal:  Endocrine       Date:  2015-04-12       Impact factor: 3.633

3.  Hematological parameters are associated with metabolic syndrome in Japanese community-dwelling persons.

Authors:  Ryuichi Kawamoto; Yasuharu Tabara; Katsuhiko Kohara; Tetsuro Miki; Tomo Kusunoki; Masanori Abe; Tateaki Katoh
Journal:  Endocrine       Date:  2013-01-10       Impact factor: 3.633

4.  A distinct metabolic signature predicts development of fasting plasma glucose.

Authors:  Manuela Hische; Abdelhalim Larhlimi; Franziska Schwarz; Antje Fischer-Rosinský; Thomas Bobbert; Anke Assmann; Gareth S Catchpole; Andreas Fh Pfeiffer; Lothar Willmitzer; Joachim Selbig; Joachim Spranger
Journal:  J Clin Bioinforma       Date:  2012-02-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.